Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Background Pralsetinib is a highly potent, selective RET inhibitor targeting oncogenic RET
alterations. We provide the registrational data for pts with RET+ MTC from the ARROW …

The FDA granted accelerated approval for pralsetinib on September 4, 2020 for non–small
cell lung cancer (NSCLC) and December 1, 2020 for thyroid cancer, for:(i) adult patients with …

Background RET mutations occur in 70% of medullary thyroid cancers, and RET fusions
occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the …

Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …

Abstract Pralsetinib (GAVRETO™, Blueprint Medicines Corporation) is a selective
rearranged during transfection (RET) inhibitor being developed for the treatment of various …

Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein
have been found in diverse thyroid cancer subtypes. RET gene rearrangements are …

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of
RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate …

Background No effective standard treatment exists for patients with radioiodine-refractory,
advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of …

A personalized approach to the management of medullary thyroid cancer (MTC) presents
several challenges; however, in the past decade significant progress has been made in both …